Director, Patient Centred Outcomes (London) in Manchester

Job Description If you are a current Jazz employee please apply via the Internal Career site. \n Jazz Pharmaceuticals is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit for more information. \n Brief Description: \n The Director, Patient-Centered Outcomes is a high-visibility, scientific, and strategic leadership role within the Global Evidence & Value Generation (EVG) organization. Reporting to the Head of Patient-Centered Outcomes, this leader will architect and execute global clinical outcome assessment (COA), patient experience data (PED), and patient-reported outcome (PRO) strategies. \n The primary mandate encompasses steering the patient-focused evidence strategies for Jazz's cornerstone oncology launch and lifecycle programs: \n \n Neuro-Oncology: Accelerating peri-launch evidence, label negotiation, and patient/caregiver-centric value demonstration in rare neuro-oncology (diffuse midline gliomas / DIPG). \n Oncology (Solid tumors): Driving registrational and lifecycle COA evidence generation across multiple solid tumor indications (including biliary tract cancer [BTC], gastroesophageal adenocarcinoma [GEA], breast cancer, and subsequent indication expansions). \n Oncology & Cross-Therapeutic Pipeline: Future-proofing early-phase assets (Phase 1b through Phase 2) by defining fit-for-purpose measurement strategies aligned to Target Product Profiles (TPPs). \n \n This role requires a commercially astute and regulatory-experienced strategist capable of balancing scientific rigor with urgent commercial and market access timelines, demonstrating the humanistic value of Jazz therapies to Health Authorities, payers, clinicians, and patients globally. \n Essential Functions/Responsibilities \n 1. Strategic Leadership for Launch & Lifecycle Brands (Neuro-Onc/Onc) \n • Neuro-Oncology Launch Leadership: \n \n Formulate and deliver patient-focused evidence packages highlighting symptom relief, functional preservation, neurological stability, and tolerability in rare neuro-oncology populations. \n Formulate specialized pediatric, adolescent, and caregiver proxy measurement strategies tailored to diffuse midline glioma/DIPG realities, addressing cognitive and motor decline. \n Execute post-hoc analyses, qualitative exit interviews, and real-world burden-of-illness studies to bolster early launch narrative, scientific publications, and reimbursement dossiers. \n \n • Oncology Global Launch & Indication Expansion: \n \n Lead end-to-end PRO and COA strategy across primary launch indications (e.g., HER2-amplified BTC) and major lifecycle expansion programs (e.g., GEA, colorectal, metastatic breast cancer). \n Design comparative patient-centered evidence strategies demonstrating superior tolerability, quality of life (HRQoL), and/or delay in physical deterioration versus standard-of-care systemic regimens. \n Partner with Global Value & HEOR (GVHEOR) to incorporate PRO endpoints into cost-effectiveness models, joint clinical assessments (EU HTA / JCA), ICER submissions, and global value dossiers (GVDs). \n \n 2. Pipeline Architecture & Early Measurement Strategy \n \n Partner with early development teams to map the measurement landscape, construct disease conceptual models, and establish COA roadmaps from Phase 1b proof-of-mechanism into Phase 2 proof-of-concept. \n Identify unmet patient-relevant needs early in development to influence Target Product Profiles (TPPs), clinical protocols, and long-term asset differentiation strategies. \n \n 3. Regulatory Strategy, Label Negotiations, & Scientific Advice \n \n Serve as the PCO lead across regulatory milestones, including briefing document authoring, Type C meetings, FDA PFDD consultations, and EMA scientific advice procedures. \n Leverage deep operational knowledge of FDA PFDD Guidances (1–4), FDA 2009 PRO Guidance, and EMA reflection papers to design endpoints eligible for product labeling and differentiation. \n Author and defend regulatory submission sections (e.g., Module 2.7.3/2.7.4 clinical summaries, Integrated Summary of Efficacy, and COA evidence dossiers) to secure regulatory label claims. \n \n 4. Scientific Rigor, Clinical Trial Integration, &am